Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.

@article{Faderl2006PhaseIS,
  title={Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.},
  author={Stefan J Faderl and Kanti Rai and John G Gribben and John C. Byrd and Ian W Flinn and Susan O'brien and Shihong Sheng and D E Esseltine and Michael J Keating},
  journal={Cancer},
  year={2006},
  volume={107 5},
  pages={916-24}
}
Therapeutic options are limited and the prognosis is poor for patients with fludarabine-refractory B-cell chronic lymphocytic leukemia (CLL). Bortezomib induces apoptosis in vitro in CLL cells, both alone and in combination, including in cells resistant to fludarabine or other agents. The aim of the current randomized, open-label, Phase II study was to investigate the clinical activity of bortezomib in patients with fludarabine-refractory B-cell CLL. Twenty-two patients with histologically… CONTINUE READING